AI is enabling the development of a next generation of drugs that can more precisely target cancer cells while sparing ...

In this interview, Technology Networks spoke with Dr. Lena Jonsson, product strategy manager at Cytiva, to explore the ...

Antibody-drug conjugates are a significant evolution in drug development landscape: Dr. Kenneth Barr: Nandita Vijayasimha, Bengaluru Saturday, April 12, 2025, 08:00 Hrs [IST] Anti ...

The theory behind antibody drug conjugates (ADCs) is simple yet elegant: by combining the specificity of a monoclonal antibody with the cytotoxicity of a potent small molecule drug, ADCs can ...

German scientist Paul Ehrlich introduced a groundbreaking concept to the world: chemical compounds could be engineered to ...

AstraZeneca has been busy in recent years pumping up its oncology pipeline via a shopping list of assets and companies. | ...

Table 1 Selected antibody–drug conjugates in Phase II or III trials ... and its expression to help design our clinical studies and to select the patient population that will have the greatest ...

In 2021, five out of the top 10 selling drugs were mAbs and this ... the first ever computationally designed antibody created by Israel-based Biolojic design entered clinical trial, further ...

Artificial intelligence has already made its mark in commercial industries, and there's a good argument to be made that AI is most impactful in the drug discovery marketplace: Drug discovery companies ...

Why ALZpath, GeneDX, 10x Genomics, Protagonist Therapeutics, and Recursion are among the most innovative biotech companies of 2025.

Vantage Market Research report examines the Antibody Drug Conjugates (ADCs) market, forecasting trends and dynamics from 2025 ...